A retrospective study of 61 acute schizophrenic patients examined whether any demographic, clinical, and outcome characteristics distinguished patients who improved with placebo or low dosages of antipsychotics (PLD patients) from patients who required high conventional dosages of antipsychotics (HCD patients). Patients in the PLD group (M = 30) and HCD group (n = 31) were similar in overall level of psychopathology at admission. Prominent excitement and certain somatic and auditory hallucinations were significantly more frequent in the HCD patients. PLD patients were more likely to be female, were hospitalized more rapidly after the onset of psychosis, and were more often first admissions. Although paranoid symptoms and premorbid schizoid personality did not differentiate the two groups, nonschizoid patients who were nonparanoid tended to be in the PLD group while nonschizoid patients who were paranoid tended to be in the HCD group. PLD patients were less psychotic at discharge, remained out of the hospital for longer periods, and had fewer rehospitalizations. These results confirm other reports of better outcome for patients successfully treated without medication. PLD patients were also functioning better as family members 1 year after discharge. Further research is indicated to improve the prediction of which acute psychotic patients will respond without medication or to low dose neuroleptic treatment and to determine if these predictions are generalizable to other treatment settings.
In the 24 years since the introduction of the neuroleptics, these agents have been established as the primary treatment for schizophrenia. Many well-controlled studies have demonstrated that the likelihood of both the diminution of symptoms in acutely psychotic patients (Klein and Davis 1969) and the prevention of relapse in chronically treated patients (Davis 1975) is significantly increased by the use of neuroleptics. Yet, because of the various short-and long-term consequences of their use, ranging from minor side effects through agranulocytosis and tardive dyskinesia, it is important to determine if there are schizophrenic patients who require only low dosages or no neuroleptic treatment at all. If this group could be identified and no or minimal neuroleptic treatment administered, the risk of developing side effects could be avoided.
There are several studies which indicate that some schizophrenics can be successfully treated as inpatients and remain out of the hospital without neuroleptic treatment. Alexander (1953, p. 204) reported that 18.9 percent of 11,080 "unselected and undifferentiated" schizophrenics attained complete recovery or full social-occupational recovery with only custodial and supportive treatment. In a more systematic study, Bockoven and Solomon (1975) compared two 5-year followup studies of newly admitted patients hospitalized in communityoriented hospitals. The first group of patients was followed from 1947 to 1952, before the introduction of antipsychoric drugs. Patients in the second group, followed from 1967 to 1972, were treated with drugs, both during hospitalization Reprint requests should be sent to Dr. Young at Illinois State Psychiatric Institute, 1601 W. Taylor St., Chicago, IL 60612. and after discharge, as was clinically indicated. At the end of 5 years, 34 of 40 (85 percent) of the nondrugtreated schizophrenic patients and 30 of 36 (83 percent) of the drug-era schizophrenics were in the community. These results indicate that, at least in terms of remaining out of the hospital at 5 years postdischarge, patients in the predrug era did as well as patients who mostly received drugs. It was also found, however, that predrug-era patients had spent more time in hospitals than had the drug-era patients. The authors suggest that this may be due to drugs having reduced inpatient treatment time or to the greater emphasis in the 1960s and 1970s on short hospitalizations. The study does not address the issues of social and work function in either cohort. In addition, it does not take into account the possible therapeutic effects of previously used biological interventions.
The response of schizophrenics to placebo has been indirectly assessed in the double-blind studies conducted to determine the clinical efficacy of neuroleptics vs. placebo. In most of the drug-placebo trials, however, only group mean improvement scores are reported. A significant finding of a greater mean improvement in the drug-treated group than the placebo-treated group does not preclude a substantial number of placebo responders. Of 11 studies cited by Klein and Davis (1969) as the largest and best controlled clinical trials of phenothiazines, only one study provides an estimate of the frequency of improvement in acutely psychotic schizophrenics given placebo or neuroleptics on a double-blind basis. That study, conducted by the National Institute of Mental Health Psychopharmacology Service Center (1964) , included 436 newly admitted acute schizophrenic inpatients treated for 6 weeks with neuroleptics or placebo. Of 270 drugtreated patients completing the trial, 95 percent improved, 75 percent in the moderate to marked range. Approximately 55 percent of the 74 placebo-treated patients completing the trial improved, 33 percent in the moderate to marked range. If the 36 patients in the placebo group who were dropped from the study because of treatment failure are included among the unimproved, 37 percent of the placebo-treated patients improved, 22 percent in the moderate to marked range. A similar study by Clark et al. (1971) found improvement in 56 percent of 18 placebo-treated patients (17 percent in the moderate to marked range) and in 87 percent of the 57 phenothiazine-treated patients. In both of these studies, there was significantly greater improvement in the drug-treated group, but as can readily be seen, a considerable number of patients did well on placebo alone.
More recently, Gottschalk (1978) studied 28 acute schizophrenic patients and found that 9 showed significant improvement during a 6-day placebo period on the Social Alienation-Personal Disorganization Scale (Gottschalk and Gleser 1969) . Carpenter, McGlashan, and Strauss (1977) studied 49 acute schizophrenics who were medicated as judged necessary. Twenty-two patients received medication and 27 patients remained drug free throughout their hospitalizations. The two groups were similar in symptomatology and prognosis at admission and were similar in outcome at 1-year followup. Mosher and Menn (1978) compared 2-year outcome data in a group of young schizophrenic (DSM-II criteria) patients who were admitted to Soteria House, a nonmedical psychological treatment program that emphasizes minimal use of antipsychotic drugs, or to a short-stay crisis-oriented service in a community mental health center that treated all patients with neuroleptic drugs. Over the 2-year followup period, there were no significant differences between the two groups in readmissions (53 percent for Soteria House, 67 percent for the control group) despite the much greater use of neuroleptics by the control group during the postdischarge period. There were also no differences in symptoms; in fact, the Soteria House patients were reported to have significantly better occupational levels and were more capable of independent living. Similarly, Rappaport et al. (1978) reported that among young first or second break schizophrenics off medication at followup, those who had been randomly assigned to placebo during hospitalization had fewer rehospitalizations and less functional disturbance than those randomly assigned to chlorpromazine.
A review of the studies of maintenance treatment in schizophrenia also indicates some schizophrenics do not require maintenance neuroleptics. Davis (1975) reviewed controlled studies of antipsychoric medication and placebo in chronic schizophrenics; 16 of the studies involved inpatients. In these studies, patients on maintenance neuroleptic medication were either continued on active medication or switched to placebo. The length of the trials varied from 6 to 39 weeks (median = 19 weeks). The relapse rates of placebo-treated patients did not increase as the length of the placebo trials increased. Examination of the 16 studies revealed that the percentage of patients who were treated 90 SCHIZOPHRENIA BULLETIN with placebo and did not relapse varied from zero to 82 percent (median = 45 percent). This represents 429 of a total of 879 placebo-treated patients. Gardos and Cole (1976) reviewed nine studies of the withdrawal of maintenance medication in schizophrenic outpatients. The length of the trials varied from 2 to 48 months; the relapse rate did not increase with the increased length of the trial. The median percent of patients receiving placebo who did not relapse in the nine studies was 37 percent (range, 17 to 69 percent). This represents 283 of a total of 605 placebo-treated patients.
The recent studies by Leff (1976) on the interaction of drug treatment and the family support system in preventing rehospitalization also indicate that some schizophrenics do not require maintenance neuroleptic therapy following discharge from the hospital. It was found that drugs played an important role in preventing relapse among patients who had much face-to-face contact with family members who had critical attitudes toward, or were emotionally overinvolved with, the patient. However, patients whose family members were less critical and not emotionally overinvolved, tended to remain out of the hospital regardless of whether they were treated with drugs. It was therefore concluded that maintenance medication can be highly beneficial for patients with poor family support systems, but that for patients with good family supports, drugs make no significant contribution to preventing rehospitalization.
It is clear from this review that a substantial number of schizophrenic patients do not require antipsychotic medication either for acute or maintenance treatment. Research on whether these patients respond to nonsomatic, psychosocial therapies or exhibit spontaneous improvement has been conflicting and is reviewed by May (1978) , Schooler (1978), and Gunderson (1980; this issue) .
The study reported here is a retrospective investigation of a group of schizophrenics who required little or no neuroleptics to recover from an acute psychotic state. Research records were examined to determine whether demographic and clinical variables differentiated these patients from a conventionally medicated group. The outcomes of the two groups were also compared.
Methods
Subjects. A total of 263 patients who were newly admitted to a research unit at the Illinois State Psychiatric Institute from September 1968 to July 1975 and who met DSM-U (American Psychiatric Association 1968) criteria for schizophrenia were considered for inclusion in the study. Patient selection criteria are summarized in table 1. The subgroup of primary interest consisted of patients who clinically improved after receiving only placebo or relatively low and possibly homeopathic dosages of neuroleptics (no more than 200 mg of chlorpromazine or its equivalent daily). A comparison group consisted of patients who required conventional but relatively high dosages of neuroleptics to achieve optimal clinical response (the equivalent of 800 mg of chlorpromazine or more daijy). No differences between these two groups were found in the specific neuroleptics used. Patients whose maximal daily dosages of neuroleptics were equivalent to 200-800 mg of chlorpromazine were not included in order to maximize the chances of finding differences between the groups. Patients were excluded who lacked essential data or who also received lithium, antidepressants, or electroconvulsive therapy. If, due to multiple hospitalizations, a patient could have been included twice, his first hospitalization only was used (multiple entry). Also excluded were patients who committed suicide, were transferred to another hospital, were discharged against medical advice (abnormal discharge), or were discharged unimproved. Thus, all subjects included in the study had responded to treatment. This last criterion was assessed by two psychologists who blindly and independently examined data from the psychosis factor of a daily raring scale (described below) (kappa = .78, p < .001). The small number of cases on which they disagreed was discussed and a consensus was reached.
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During the period chosen for study, medication was prescribed on a single-blind, doctor's choice basis. All patients initially received placebo (three capsules twice daily). At the end of a 7-day period, if the patient was still at least moderately symptomatic, the equivalent of 100 mg chlorpromazine b.i.d. was begun by substituting identically appearing capsules for placebo. Medication was increased by 100 mg b.i.d. weekly until optimal clinical improvement was achieved. Very difficult management problems had their medication dosages raised more rapidly.
Nine patients who improved sufficiently during the first week were continued on placebo and, because satisfactory improvement continued thereafter, neuroleptic treatment was never started. Twenty-one patients achieved marked improvement with the equivalent of 200 mg chlorpromazine, so their medication dosage was never increased. This dosage is generally considered to be subtherapeutic for the treatment of newly hospitalized, acutely psychotic schizophrenics (Klein and Davis 1969) . In a different group of patients similarly treated, we have found low serum prolactin levels and low serum neuroleptic levels which support the contention that these dosages are subtherapeutic (H.Y. Meltzer et al., unpublished data). These patients were therefore combined with the placebo-treated subjects on the grounds that we had intervened prematurely and that they probably had not needed neuroleptic therapy. Although we cannot be absolutely certain that patients on low dosages were not exceptional in their biological responses to these dosages, subsequent analyses showed that they were highly similar to placebo patients on all the variables we studied. Our selection process yielded two final samples, referred to as the placebo-low dosage (PLD) group (n = 30) and the high conventional dosage (HCD) group (« = 31).
All patients also participated in an intensive milieu therapy program. The treatment facility consisted of a 14-bed ward to which only voluntary patients who consented to participate in research were admitted. The population consisted primarily of patients with a recent onset of florid psychotic symptoms. The role of medication in the inpatient phase of treatment was deemphasized and a structured clinical setting aimed at minimizing ambiguity was stressed. Clear expectations of social functioning and firm limits on bizarre behavior were set by the staff, with the assistance of patients well along in recovery and family members. Families of patients attended multiple family group meetings twice weekly to help families better understand the patient's illness and to work with patients on stressful social and interpersonal situations that may have contributed to the patient's condition. Patients' days were heavily structured with group meetings and occupational and recreational therapy. There was no structured individual psychotherapy, but a great deal of informal therapeutic interaction took place between individual staff members and individual patients. Inpatient stays were generally from 2 to 3 months. Great emphasis was placed on making good aftercare plans and ward staff provided a variety of outpatient therapies.
Demography. Data on age, sex, race, marital status, and social status were collected by the research social worker.
Clinical Characteristics. Criteria for chronicity approximated those of the Research Diagnostic Criteria (Spitzer, Endicott, and Robins 1975) . Criteria for paranoid status and schizoid personality were those of DSM-II. The number of previous hospitalizations and the number of days from onset of psychosis to hospitalization were assessed by the research social worker from interviews of first degree relatives as well as the index patients. Prognosis was assessed by the prognosis scale of Stephens, Astrup, and Mangrum (1966) using the interview data.
Symptomatology. The seven symptom items of the StephensAstrup-Mangrum Scale were used to assess symptomatology. These data were collected by the ward psychiatrists and the research social worker. The items include: (1) prominent excitement; (2) confusion or disorientation; (3) marked emotional blunting; (4) feelings of guilt; (5) depressive features; (6) haptic or sexual hallucinations or hallucinations of the patient hearing his own thoughts, voices commenting on his movements or voices from within his body (specific hallucinations); and (7) thought disturbances characterized by delusions of depersonalization, influence, passivity, or disturbance of symbolizations.
Symptomatology was also evaluated using a 14-item version of the rating scale devised by Hargreaves (1968) . Each patient was rated weekdays by the ward staff; higher ratings are indicative of greater symptomatology. The mean pooled interrater reliability for all raters was .90. A principle component factor analysis of the first week peak clinical symptom ratings for 232 schizophrenic patients yielded three independent dimensions of symptomatology. These dimensions were labeled Psychosis, Agitated-Anger, and Retarded-Depression, based on the clinical symptoms that loaded on each dimension. The alpha coefficients of reliability for each of the scales were: Psychosis, .94, Agitated-Anger, .82, and RetardedDepression, .72. These scale scores were used to compare the two dosage groups on psychopathology at admission and discharge.
Outcome. The social functioning of all patients who could be located and would cooperate was assessed 1 and 2 years after discharge. The 1-year followup consisted of a mailed questionnaire for which the patient rated his level of functioning in various interpersonal and work-related activities and provided rehospitalization information (n = 35). The 2-year followup consisted of a brief questionnaire, including rehospitalization information, and the patient's form of the Katz Adjustment Scale (Katz and Lyerly 1963) {n = 38). Additional data on rehospitalization were obtained from records of hospitalizations in state mental health facilities through December 1978, which would include most rehospitalizations for these patients.
Results
Demographics. The patients in the PLD and HCD groups did not significantly differ in race, age, marital status, or social status (table 2) . Females were more frequently in the PLD group (61 percent) than were males (30 percent) (x 2 = 4.06, p < .05).
Clinical Characteristics. The clinical characteristics of the PLD and HCD groups are presented in table 3. Patients were distributed between the groups significantly differently according to their number of previous hospitalizations (x 2 = 6.01, p < .05). Sixty-seven percent of all first admis- sions were in the PLD group, while 64.7 percent of patients with previous hospitalizations were in the HCD group. The number of days from onset of psychosis to hospitalization also significantly differentiated between the groups (x 2 = 7.33, p < .01). Two-thirds of patients admitted within 7 days of onset were in the PLD group, whereas 71 percent of patients admitted more than 7 days after onset were in the HCD group. Once admitted, the PLD group had a shorter mean hospital stay (53.5 days) than did the HCD group (70.2 days), although this difference was not significant (t = 1.88, p < .07). The two groups did not differ significantly in the proportion of patients with schizoid premorbid personalities or with diagnoses of paranoid type. When these two variables were considered jointly, a nonsignificant trend (p < .10) was observed. Nonschizoid nonparanoid patients tended to be overrepresented in the PLD group; nonschizoid paranoid and schizoid nonparanoid patients tended to be overrepresented in the HCD group.
No differences between the two groups were observed on the following variables: the proportions of patients with acute and chronic illnesses, neuroleptic treatment immediately before admission, total Stephens-Astrup-Mangrum prognosis score, clear precipitating events, blood relatives with schizophrenia-like psychoses, and the onset of psychosis within 6 months of hospitalization. Outcome. Figure 1 shows the survival rates for the two groups as calculated by the life table method (Fleiss et al. 1976) . A comparison of the two curves by a procedure described by Mantel (1966) indicates that the PLD group was significantly more likely to remain out of the hospital (x 2 = 10.50, p < .01). Differences between the groups began to appear 6 months after discharge. Table 7 shows the number of rehospitalizations through December 1978 for each group. The PLD group had significantly fewer rehospitalizations (x 2 = 14.87, p < .01). The number of rehospitalizations was not related to the time from index discharge to final assessment (r = -.12).
There was also a significant difference between the two groups in their functioning as family members 1 year after hospitalization (table 8). None of the PLD patients reported poor functioning as a family member 1 year after discharge. In contrast, 33 percent of the HCD patients reported poor functioning in this area. Thirty-six percent of the PLD patients were taking medication 1 year after discharge, compared to 64 percent of the HCD patients, but this difference was not significant. The groups reported no differences in meeting family responsibilities, work behavior, interpersonal relationships, frequency of recreational activity, and participation in outpatient treatment. These results should be interpreted with caution since only about half the patients responded to the 1-year followup questionnaire.
Over 50 percent of the patients completed the Katz Adjustment Scale at 2-year followup. T-tests comparing the mean scores on each scale for the dosage groups were not significant. It should be noted, however, that the 2-year followup did not assess family functioning as specifically as did the 1-year followup. Thus, it may be that the PLD group was still functioning better as family members 2 years after discharge.
Discussion
Our original intention in treating patients with placebo and then gradually increasing dosages of neuroleptics was not one of carrying out a systematic inquiry into the features of patients who responded to placebo or low dosages and patients who did not. Rather, it seemed clinically desirable to administer no more potentially toxic medication than was necessary. Having done this over a period of years, we felt a retrospective comparison of patients who did well on placebo or low dosages of neuroleptics with patients who required more conventional dosages would be valuable. The patients included in our report all received diagnoses of schizophrenia based upon DSM-II criteria. They would also meet the criteria for schizophrenia of the New Haven Schizophrenia Index (Astrachan et al. 1972 ) because of the presence of psychotic symptoms, including delusions, hallucinations, formal thought disorder, and/or bizarre behavior. These criteria are too broad for current narrow diagnostic criteria for schizophrenia (e.g., the Research Diagnostic Criteria of Spitzer, Endicott, and Robins 1975) because they do not exclude atypical affective disorders. However, it should be recalled that patients whose affective symptoms were sufficiently pronounced for them to have been treated with lithium, antidepressants, or electroconvulsive therapy at any rime during their index hos- pitalizations were excluded in the original selection of patients for this analysis. Additional diagnostic information was available for 49 of the 61 patients (80 percent) from previous admissions, subsequent hospitalizations, and from our own outpatient clinic where some of these patients are still being seen. Of these patients the diagnosis of schizophrenia by current more restrictive criteria, which emphasize chronicity and exclusion of patients with affective symptoms, was not supported or was considered suspect in 7 of 19 PLD patients (37 percent) and 7 of 30 HCD patients (23 percent). The difference between the proportion of patients with suspect diagnoses in the two groups is not significant. It was not possible to get a further diagnostic assessment for the 12 of 61 patients (20 percent) who, to the best of our knowledge, had no previous or subsequent hospitalizations. In any event, it seems justifiable to conclude that our sample is similar to those used in the large body of clinical research which predates the Research Diagnostic Criteria (Spitzer, Endicott, and Robins 1975) and that some patients who by current standards would not be considered schizophrenic are included. Those analyses which we report as significant or nearly significant, have been, repeated with the 14 probable nonschizophrenics omitted; this yielded different results for only specific hallucinations, which were no longer significantly more prevalent in the HCD group. Of the 263 patients originally diagnosed as schizophrenic, 30 were successfully treated with placebo or very low doses of neuroleptics, although only 9 patients received placebo alone. This low figure is in part due to the fact that if patients did not show marked improvement within a week of admission, neuroleptics were started. The studies cited in the introduction which had much larger percentages of placebo responders also used much longer placebo treatment periods. Whether these patients responded to continued administration of placebo, or whether this low dosage was therapeutic, is impossible to determine retrospectively. Abse, Dahlstrom, and Tolley (1960) and Hamill and Fontana (1975) have reported no differences in clinical response to placebo and daily dosages of 300 to 600 mg of chlorpromazine for 1 week in newly admitted acutely Table 8 . One-year followup psychotic schizophrenics. These reports suggest that, on a group basis, brief treatment with lower doses of chlorpromazine may not have a statistically significant benefit. Wode-Helgodt et al. (1978) , on the other hand, report that, following 2 weeks of treatment with 200, 400, or 600 mg chlorpromazine, the clinical responses of female schizophrenics were equal; however, clinical response in males was observed only in those patients in higher dosage groups, a finding which suggests that 200 mg chlorpromazine is a subtherapeutic dose. In our PLD group, 14 of 30 patients were females who received the equivalent of 200 mg of chlorpromazine daily. Although Wode-Helgodt et al. (1978) label their three groups by their final daily dosages of 200, 400, and 600 mg, there was, in fact, a slow buildup to these dosages. Thus, the mean daily dosages for the three groups were actually 179, 250, and 250 mg for the first week of treatment and 200, 400, and 557 mg for the second week. This may contribute to the failure to find differences in clinical response at 2 weeks in females. Although these studies do not resolve the question of the therapeutic activity of the equiva- lent of 200 mg of chlorpromazine in our patients, it is safe to conclude that the HCD group did not respond as rapidly to this dosage (and 400 and 600 mg daily as well) as did the PLD group to placebo or 200 mg of chlorpromazine.
We will now examine the demographic, clinical, and outcome differences found between the PLD and HCD groups with a view toward determining what relationship, if any, they have to neuroleptic medication requirements. We will also discuss the prognostic significance of PLD status.
The fact that two-thirds of patients whose index admission was their first psychiatric hospitalization were in the PLD group is clearly of importance. They constitute 60 percent of the PLD group. Since PLD first admission patients had significantly fewer readmissions than did HCD first admission patients (table 9), this PLD subgroup may have had a less malignant form of psychosis than the comparable subgroup of HCD patients. Of the 14 first admission patients who were never readmitted during our followup period (5 to 10 years for these patients), 13 (93 percent) were in the PLD group. It is intriguing to speculate whether not being treated intensively with drugs contributed to the good outcome of these first admission patients. reported that schizophrenics randomly assigned to placebo had fewer hospitalizations in the year following discharge than those randomly assigned to neuroleptics. Similar results were reported by Rappaport et al. (1978) . Previously hospitalized patients have been ill and/or treated with drugs for longer periods of time than those not previously hospitalized. Either fact may account for the higher incidence of HCD status in previously hospitalized patients.
It might be expected that HCD patients were more symptomatic at admission than were the PLD patients. However, the two groups did not differ in overall psychopathology. Carpenter, McGlashan, and Strauss (1977) have also found no differences in overall levels of psychopathology at admission between patients who did and patients who did not require medication within a milieu treatment program. The HCD patients were more likely to show prominent excitement than were PLD patients. Patients with prominent excitement present greater management problems and may have been given more medication on this basis. HCD patients were also more likely .to have certain specific hallucinations. Whether this or other specific symptoms will prove to be reliable indicators of the small subgroup of schizophrenics who will rapidly remit on placebo or low dosages of neuroleptic is a question of considerable clinical significance.
Patients were more likely to be in the PLD group if they were hospitalized within 7 days of the onset of psychotic symptoms. PLD patients may have more dramatic onsets or their families may be more observant and/or less tolerant of the changes Females were more likely to be in the PLD group, whereas males were more likely to be in the HCD group. An examination of dosage increases in the HCD group shows that males were medicated more quickly than females. Thus a greater number of males than females may have been eliminated from the PLD group by being highly medicated before potential improvement with lower dosages could occur. The overrepresentation of females in the PLD group may therefore be an artifact of dosing practice. Alternatively, males may have required higher dosages than females because of greater body weight or other factors. It is also possible that our milieu treatment was more effective for females. have reported that male schizophrenics showed a greater reduction in symptoms on placebo than females. Both male and female schizophrenics were found to improve significantly more on drug than placebo, but the difference was less for males. These results, however, are not directly comparable to those reported here since their patients were randomly assigned to treatment, and only mean group improvement scores are reported.
While both the PLD and HCD groups significantly improved and all patients were discharged as im-proved, PLD patients were found to be less symptomatic at discharge than were HCD patients. This was the case despite (1) the finding that they were similar to HCD patients in level of pathology at admission, (2) they had received no medication or dosages at least four times lower than the HCD group, and (3) they had been treated for an average of 13 fewer days than had HCD patients. Carpenter, McGlashan, and Strauss (1977) have also reported that patients who did not receive medication had shorter hospitalizations than medicated patients, but Mosher and Menn (1978) reported the opposite. However, in Mosher and Menn's study, unmedicated patients were treated in a totally different setting from medicated patients, who were treated in a control facility where rapid patient turnover was emphasized. By contrast, our patients and those of Carpenter, McGlashan, and Strauss, medicated and unmedicated, were treated in the same milieu. In our study, it is possible that, since dosage was usually increased gradually, the 13 days' difference in length of hospitalization represents the time required for HCD patients to reach therapeutic dosages. Goldstein (1970) has suggested that schizophrenics with good premorbid histories, as measured by the Phillips Scale of Premorbid Adjustment (Phillips 1953), do as well without medication as they do with medication. However, the PLD and HCD group did not differ on the StephensAstrup-Mangrum scale or on marital status and schizoid personality, which most closely approximate the Phillips prognosis scale. Our findings agree with those reported by Carpenter, McGlashan, and Strauss (1977) in their study of patients who received milieu therapy with drugs administered only as necessary.
Findings by Judd et al. (1973) and Goldstein (1970) suggest that, among patients with good premorbid histories, paranoid patients appeared to require medication. Nonparanoid, good premorbid patients did equally well on placebo or medication. These results agree with the trend found here that the nonparanoid nonschiz.oid patients were more likely to be in the PLD group, while paranoid nonschizoid patients were more likely to be in the HCD group. , on the other hand, found that paranoid symptoms improve equally well with drug or placebo treatment. This result is supported by Kellam et al. (1967) , who found that paranoid symptoms were more susceptible to the ward environment than were withdrawal symptoms. While these latter findings appear opposite to those of Judd et al. (1973) and Goldstein (1970) they are not directly comparable since some paranoid symptoms may occur in patients who do not fulfill criteria for paranoid schizophrenia.
PLD patients were found to be functioning better as family members at 1-year followup than were HCD patients. Leff (1976) has reported that patients with good family relations do equally well with or without medication as outpatients. If one can assume that the PLD patients also had good family relations at the time of their hospitalizations, it is suggestive that such patients also do not require medication as inpatients. This may be especially true in a milieu setting such as the one used here, which included family therapy. The possibility that poor relations with the family may increase the need for medication during hospitalization if the family is involved in treatment should be explored.
PLD patients were found to have a lower readmission rate at all time periods from 1 to 3 years after discharge. The PLD patients also had fewer rehospitalizations in the 3-to 10-year period from their discharge to final followup. This finding was not the result of the period of time over which rehospitalizations were tabulated. As of December 1978, 60 percent of the PLD patients had never been re hospitalized, whereas only 26 percent of the HCD patients had never returned to the hospital. Trends in this direction have also been reported by Carpenter, McGlashan, and Strauss (1977) .
The fact that the HCD group was found to be somewhat more psychotic at discharge is a potential factor contributing to its poorer outcome. The actual difference, however, was not great enough to suggest this as the sole factor in determining outcome differences. have reported that patients randomly assigned to inpatient placebo treatment were less likely than drug-treated patients to be rehospitalized during the first year following discharge. Prien, Levine, and Switalski (1971) have noted that, when placebo was substituted for active medication, patients who had received higher dosages were more likely to relapse than patients who had received little or no medication. Also, Gardos and Cole (1976) have noted a trend suggesting that patients who relapse while receiving medication have a considerably higher rehospitalization rate than do patients who relapse on placebo. Matthews et al. (1979) also reported a higher risk of relapse for patients maintained on drugs than for drug-free patients. These findings are in agreement with those reported here that patients who require little 100 SCHIZOPHRENIA BULLETIN or no medication as inparients have a lower rehospitalization rate than do patients who require high dosages of neuroleptics. Whether this is a result of the nature of these patients, the milieu treatment they received, or the absence of drug treatment is a provocative question that this study cannot answer.
The present study was not designed to assess the effects of the milieu therapy that all patients received. Although the PLD patients improved while receiving essentially milieu therapy alone, a control group receiving placebo without milieu therapy would be necessary to demonstrate the degree to which improvement was a result of the milieu. It is also uncertain to what extent our results can be generalized to other treatment environments. In addition, the importance of a placebo effect in the recovery of the PLD patients cannot be ascertained.
It is clear from our study and previous studies that a significant number of newly admitted patients, schizophrenic by traditional, relatively broad American criteria, can be successfully treated with placebo or very low doses of neuroleptics. These patients were more likely to be female, first admission, and hospitalized within a week of the onset of psychosis. They were less likely to have prominent excitement or certain specific somatic or auditory hallucinations. Nonparanoid patients with nonschizoid premorbid personalities also tended to be in the group. A discriminant analysis showed that, for the current sample, these variables could be used to identify PLD patients. Since this study was conducted retrospectively, the results can only be taken as indicators that should be investigated further. However, at our current state of knowledge, given the risk of longterm side effects and the possible superior prognosis for patients who remit without medication, it appears worthwhile to consider a trial of placebo or low dosage treatment before initiating high dosages of neuroleptics in those schizophrenic patients who best approximate the criteria for the PLD group described here.
